In addition to the SP-26 agreement, Kymanox is Silo’s regulatory partner for SPC-15, a targeted prophylactic treatment for stress-induced affective disorders including PTSD.

The following is a summary of “Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies,” published in the ...

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced an extension of its cooperative research and development agreement ...

The Amphastar Pharmaceuticals' logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene MIST ®, Amphadase ®, Cortrosyn ®, REXTOVY ® and ...

Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect ...

According to Alnylam’s Tim Mooney, mivelsiran’s endurance is due to stabilizing tweaks the scientists made to the siRNA ...

Virpax Pharmaceuticals shares are up 59.4% after announcing an extended collaboration with NCATS to advance its NES100 pain management candidate. Virpax also announced results from a minipig Dose ...

A grant from the ALS Association will fund an early-stage clinical trial to test Tiziana's foralumab nasal spray in 20 ALS ...

The intranasal brain delivery system, which is in phase II clinical trials, is already helping patients whose tumors had previously stopped responding to treatment.

Tiziana Life Sciences (TLSA) has released an update. Tiziana Life Sciences has secured funding from the ALS Association to ...

A research article shows that Eradivir's patent-pending antiviral therapeutic called EV25 reduces lung viral loads of advanced-stage influenza in preclinical studies quicker and more effectively than ...

Both the nasal and IV forms of bumetanide had a variability in absorption of 27%, suggesting a more stable route of dosing ...